(EMAILWIRE.COM, March 09, 2019 ) According to the new market research report ""US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based) - Forecast to 2022", published by MarketsandMarkets™,  The US anticoagulation therapy market has witnessed a healthy growth rate during the last decade and is expected to grow at a CAGR of 8.5% between 2017 and 2022 to reach USD 27.83 Billion by 2022. 

Get Free Sample Pages @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114158575

In this report, the US anticoagulation therapy market is segmented on the basis of products and clinics. On the basis of products, the market is segmented into anticoagulation drugs and PT/INR testing devices.

Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs. In 2016, the NOACs segment dominated the US anticoagulation therapy market for drugs. Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs. In addition, key market players such as Portola Pharmaceuticals (received FDA approval for its NOAC Betrixaban in July 2017) are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamics. Consequently, many other companies are also expected to focus on developing more safe and efficient NOACs in the coming years; this will ensure the continued growth of this segment.

The anticoagulation therapy market for clinics is segmented on the basis of type of services and clinics. The types of clinics include hospital associated clinics, independent clinics, and pharmacy-based clinics while the types of services include testing services and consulting services. The pharmacy-based clinics segment is expected to register the highest CAGR during the forecast period. In the US, the number of pharmacy-based anticoagulation clinics has increased significantly in the last few years. This is due to the fact that better results are achieved when therapy is managed by expert pharmacists rather than care provided by family physicians. Moreover, the cost of therapy provided by pharmacy-based anticoagulation clinics is comparatively lesser than independent and hospital associated anticoagulation clinics which is expected to drive the market for pharmacy-based anticoagulation clinics.

Get 10% Free Customization @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=114158575  

C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and Portola Pharmaceuticals (US) are the major market players in the US anticoagulation therapy market for drugs while Roche (Switzerland), Abbott (US), Siemens (Germany), Alere (US), and CoaguSense (US) are the major market players in the US anticoagulation therapy market for PT/INR home testing devices.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: 1-888-600-6441

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com